npj Precision Oncology

npj Precision Oncology is an online-only fully open access journal of the npj Series published by Nature Portfolio in partnership with The Hormel Institute of the University of Minnesota, launched in 2017 and devoted to basic, translational and clinical research in precision oncology, which it defines as cancer diagnosis, prognosis, prevention and treatment tailored to the individual patient on the basis of the genetic or molecular profile of that patient, with a 2025 Journal Impact Factor of 9.9 in the oncology category《精准肿瘤学》（npj Precision Oncology）是（Nature Portfolio）旗下的纯在线完全开放获取期刊，属（npj Series）丛书，与明尼苏达大学霍梅尔研究所（The Hormel Institute）合作出版，2017 年创刊，致力于精准肿瘤学的基础、转化与临床研究——该刊把精准肿瘤学界定为依据患者的遗传或分子特征为个体患者量身定制的癌症诊断、预后、预防与治疗，2025 年肿瘤学类影响因子为 9.9。

Scope

• The journal considers research covering all aspects of basic science, translational work and clinical research in precision oncology, and it states that it welcomes innovative, well-conducted and deep studies该刊考虑精准肿瘤学中基础科学、转化工作与临床研究的所有方面，并声明欢迎具有创新性、设计严谨且挖掘深入的研究。
• Among its listed topics are targeted therapy and precision medicine clinical trials and therapeutic strategies, together with biomarker studies that include both biological and external validation in an independent cohort其所列主题包括靶向治疗与精准医学临床试验及治疗策略，以及同时具备生物学验证与独立队列外部验证的生物标志物研究。
• It covers immunotherapies, immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines and immunomodulatory agents for personalised cancer treatment, and the applications of liquid biopsy techniques, including circulating tumour DNA, circulating tumour cells and exosomes, for non-invasive cancer detection, monitoring and assessment of treatment response其范围涵盖用于个体化癌症治疗的免疫疗法、免疫检查点抑制剂、过继细胞治疗、肿瘤疫苗与免疫调节药物，以及循环肿瘤 DNA、循环肿瘤细胞与外泌体等液体活检技术在无创癌症检测、疗效监测与治疗反应评估中的应用。
• Tumour heterogeneity, clonal evolution and the dynamics of the tumour microenvironment in progression, metastasis and therapy resistance are in scope, as are genomic profiling, molecular characterisation of cancer and the mechanisms of drug resistance with their therapeutic countermeasures肿瘤异质性、克隆演化以及肿瘤微环境动态在进展、转移与治疗耐药中的作用均属收稿范围，基因组谱型、癌症分子表征与治疗耐药机制及其应对策略亦然。
• It also takes clinical applications of predictive modelling, artificial intelligence and computational oncology, including large language model studies for research or clinical use and deep learning analyses with external validation and clear clinical potential, and pharmacogenomics including secondary analyses of clinical trial datasets, while microbiome work is considered only with clear evidence of relevance to a precision oncology treatment该刊亦接收预测建模、人工智能与计算肿瘤学的临床应用，包括面向科研或临床的大语言模型研究以及具备外部验证与明确临床潜力的深度学习分析，还接收药物基因组学与临床试验数据集的二次分析，而微生物组研究仅在有明确证据表明其与某种精准肿瘤治疗相关时才予考虑。
• Its content types comprise original research, brief communication, perspective, review, comment, protocol and case report, alongside guest edited collections that authors may propose and submit to其文章体裁包括原创研究、简短通讯、观点、综述、评论、实验方案与病例报告，并设有可由作者提议并投稿的客座编辑合集。
• As a fully open access title it makes every article freely and permanently available online immediately upon publication with no subscription or registration barrier and leaves copyright with the authors, and it is abstracted and indexed in the Science Citation Index Expanded, Scopus, PubMed Central, EMBASE, Chemical Abstracts Service and Current Contents, among others作为完全开放获取期刊，它在文章刊出即刻提供免费而永久、无订阅与注册门槛的在线获取，版权仍归作者，并被（SCIE）、（Scopus）、（PubMed Central）、（EMBASE）、（CAS）与（Current Contents）等检索系统收录。

History

• The journal was launched in 2017 within the npj Series of online-only open access titles, and its first papers were published on 20 March 2017, among them a programmatic essay on precision oncology as the future of personalised cancer medicine by Ann M. Bode and Zigang Dong该刊于 2017 年在（npj Series）在线完全开放获取丛书内创刊，首批论文发表于 2017 年 3 月 20 日，其中（Ann M. Bode）与（Zigang Dong）撰写的纲领性文章把精准肿瘤学称作个体化癌症医学的未来。^[1]
• Also appearing in that first tranche was a review of overcoming resistance to targeted therapies in lung cancer written jointly with the journal's present editor-in-chief, and the catalogue of the National Library of Medicine records the Hormel Institute as the corporate body behind the serial同批刊出的还有一篇关于克服肺癌靶向治疗耐药的综述，由该刊现任主编参与撰写；美国国家医学图书馆目录把霍梅尔研究所列为该刊的团体责任者。
• The National Library of Medicine records the serial as published in London by Springer Nature from 2017, with the first issue described as 1:1 of 2017, an electronic-only ISSN of 2397-768X, a starting year of 2017 and entry into PubMed and PubMed Central from volume 1 issue 1美国国家医学图书馆记录该刊自 2017 年起由（Springer Nature）在伦敦出版，著录基准为 2017 年第 1 卷第 1 期，仅有电子版 ISSN 2397-768X，起始年 2017，并自第 1 卷第 1 期起入（PubMed）与（PubMed Central）。
• Its partner has been recorded as The Hormel Institute of the University of Minnesota, a cancer research institute started in 1942 by Jay C. Hormel and expanded in 2016 by twenty further laboratories, whose laboratories in Austin, Minnesota pursue drug discovery and development alongside cancer prevention该刊的合作方记为明尼苏达大学霍梅尔研究所——由（Jay C. Hormel）于 1942 年创办、2016 年扩建新增 20 个实验室，其在奥斯汀（明尼苏达州）的实验室在癌症预防之外兼及药物发现与开发。
• Articles are numbered continuously within a single annual volume, so that the growth of the journal is measured by article number rather than by issue, and volume 10 of 2026 had already passed article 397 by October文章在同一年度卷内连续编号，因此该刊的扩张以文章号而非期号衡量，2026 年第 10 卷到 10 月已越过第 397 号文章。
• Its impact factor was 8.254 for 2021 and 10.092 for 2022, 8.0 for 2024 and 9.9 for 2025, and by 2026 the publisher had registered more than sixteen hundred articles with the DOI prefix of the series其影响因子 2021 年为 8.254，2022 年为 10.092，2024 年为 8.0，2025 年为 9.9，至 2026 年出版方已在该丛书 DOI 前缀下注册文章逾一千六百篇。

Editors

• Trever Bivona, professor of medicine and of cellular and molecular pharmacology at the University of California San Francisco, is editor-in-chief, a physician scientist whose programme concerns signal transduction, cancer genetics and the molecular basis of tumour initiation, progression and drug resistance（Trever Bivona）任主编，为加州大学旧金山分校（University of California San Francisco）医学与细胞分子药理学教授，是研究信号转导、癌症遗传学以及肿瘤发生、进展与耐药分子基础的临床科学家。
• Deputy editors hold named section remits, among them Matthew Gubin of the University of Texas MD Anderson Cancer Center for tumour microenvironment and immunotherapy and Jakob Nikolas Kather of Heidelberg University for artificial intelligence and computational oncology together with biomarkers and diagnostics副主编各带具名领域，其中得克萨斯大学 MD Anderson 癌症中心的（Matthew Gubin）负责肿瘤微环境与免疫治疗，海德堡大学（Heidelberg University）的（Jakob Nikolas Kather）负责人工智能与计算肿瘤学以及生物标志物与诊断。
• Fresia Pareja of Memorial Sloan Kettering Cancer Center edits the genomics, transcriptomics and proteomics section and Pradeep Chaluvally Raghavan of the Medical College of Wisconsin the sections on tumour biology and translational cancer biology纪念斯隆凯特琳癌症中心（Memorial Sloan Kettering Cancer Center）的（Fresia Pareja）主持基因组学、转录组学与蛋白质组学领域，威斯康星医学院（Medical College of Wisconsin）的（Pradeep Chaluvally Raghavan）主持肿瘤生物学与转化肿瘤生物学领域。
• Further deputy editors include Lydia Cheung of the University of Texas Health Science Center at Houston, working on functional cancer genomics and therapeutics, and Xiaofeng Jiang of TU Dresden, developing multimodal artificial intelligence models for survival prediction in colorectal cancer其他副主编还包括休斯敦得克萨斯大学健康科学中心（University of Texas Health Science Center at Houston）从事功能癌症基因组学与治疗研究的（Lydia Cheung），以及德累斯顿工业大学（TU Dresden）开发结直肠癌生存预测多模态人工智能模型的（Xiaofeng Jiang）。
• Beneath them sits a body of associate editors drawn from institutions such as St. Jude Children's Research Hospital, the Icahn School of Medicine at Mount Sinai and the University of Kansas Medical Center, and manuscripts are assessed by single anonymised peer review under the policies of the publisher其下另有来自圣犹达儿童研究医院（St. Jude Children's Research Hospital）、西奈山伊坎医学院（Icahn School of Medicine at Mount Sinai）与堪萨斯大学医学中心（University of Kansas Medical Center）等机构的助理编辑群体，稿件按出版方政策经单匿名同行评审评估。